Harris & Harris Group

Chief Financial Officer and Managing Director since 2008

Mr. Wolfe joined Harris & Harris Group in 2004. Prior to joining the Company, Mr. Wolfe was a consultant to Nanosys, Inc., CW Group, and Bioscale, Inc., and was the Co-founder and President of Scientific Venture Assessments, Inc., a provider of scientific analysis of prospective investments for private equity placements and of scientific expertise to high-technology companies. He was graduated from Harvard University with a Ph.D. and A.M. in Chemistry. He was a NSF Predoctoral Fellow at Harvard, and his thesis advisor was Professor George Whitesides. He was also graduated from Rice University with a B.A. in Chemistry, where he worked with Professor Naomi Halas, and his honors included the Zevi and Bertha Salsburg Memorial Award in Chemistry and the Presidential Honor Role. He has published over 15 articles in scientific peer-reviewed journals.

Portfolio responsibilities: Ensemble Discovery, Kereos, Nanosys, Nextreme Thermal Solutions, SiOnyx and Zia Laser.

	CHARLES E. HARRIS Chairman of the Board and Chief Executive Officer / Managing Director since 1984 Prior to 1984, Mr. Harris had an 18 year career in the investment industry, including serving as Chairman of Wood, Struthers and Winthrop Management Corp., the investment advisory subsidiary of Donaldson, Lufkin & Jenrette. He is a past Trustee, and current Co-Chairman of the President’s Council, of Cold Spring Harbor Laboratory (CSHL), a research and education institution in molecular biology and genetics, and a current Trustee and Chairman of the audit committee of Nidus Center, a life sciences business incubator. He is a life-sustaining fellow of the Massachusetts Institute of Technology and a Shareholder of its Entrepreneurship Center. He was a member of the Advisory Panel for the Congressional Office of Technology Assessment. He was graduated from Princeton University (A.B.) and the Columbia University Graduate School of Business (M.B.A.). Portfolio responsibilities: Alpha Simplex, Exponential Business Development, Mersana Therapeutics, Nantero, Questech and SiOnyx.

	DOUGLAS W. JAMISON President, Chief Operating Officer and Managing Director since 2005 From 2002 to 2004, Mr. Jamison served as Vice President of Harris & Harris Group. Mr. Jamison also served as Chief Financial Officer from 2005 to 2007. Prior to joining the Company, Mr. Jamison worked for five years as a Senior Technology Manager at the University of Utah Technology Transfer Office, where he managed intellectual property for the University of Utah. This included assessing technologies in both the biological sciences and the physical sciences, working with patent attorneys to develop patent protection, and developing and marketing these technologies with industry. He is a Co-Editor-in-Chief, Journal of Nanotechnology Law & Business and Co-Chair of the Advisory Board, Converging Technology Bar Association. He was graduated from Dartmouth College (B.A.) and the University of Utah (M.S.). Portfolio responsibilities: Ancora Pharmaceuticals, Chlorogen, Metabolon, Nextreme Thermal Solutions, Solazyme and Starfire Systems.


	ALEXEI A. ANDREEV, PH.D. Executive Vice President / Managing Director since 2005 Prior to joining Harris & Harris Group, Mr. Andreev was an Associate with Draper Fisher Jurvetson (DFJ), a venture capital firm, where he was exclusively focused on nanotechnology and material science investment opportunities. While at DFJ, he played an integral role in sourcing and funding EoPlex, Intematix, Solicore and D-Wave Systems, for which companies he served as an active Board Director or Observer. Previously, he worked for TLcom Capital Partners, a London-based venture capital fund backed by Morgan Stanley. Prior to that, he was employed by Renaissance Capital Group/Sputnik Funds, a venture capital fund in Moscow, Russia. Before he started his business career, he was a researcher at the Centre of Nanotechnology, ISAN (RAS), in Troitsk, Russia, where he was focused on optical and electrical properties of Quantum Dot heterostructures. He was graduated from the Department of Theoretical Physics of Moscow Steel & Alloys Institute with a Ph.D. degree, where he was a recipient of the Scholarship for Outstanding Young Scientists of Russian Academia of Sciences, the Scholarship from the International Center of Fundamental Physics and Soros Scientific Foundation. He also was graduated from Moscow Steel & Alloys Institute with a B.S. with honors in Engineering/Material Sciences and from Stanford Graduate School of Business with an M.B.A. He is a co-founder and Director of the American Business Association of Russian Expatriates (AmBar). Portfolio responsibilities: C-Switch, D-Wave Systems, Kovio, Lifco, Molecular Imprints, NanoGram, NeoPhotonics and Xradia.

	MICHAEL A. JANSE Executive Vice President / Managing Director since 2007 Prior to joining Harris & Harris Group, Mr. Janse was a Principal at ARCH Venture Partners in the firm's Chicago office, focusing on nanotechnology, semiconductors and advanced materials technologies. His role included a particular focus on technologies emanating from universities, research labs and national labs. Prior to ARCH, Mr. Janse worked in Motorola's Semiconductor Products Sector as a process engineer, and later marketed semiconductor components to manufacturers of personal computers and networking products. He was holds an M.B.A. from The University of Chicago, and a B.S. in Chemical Engineering from Brigham Young University. Portfolio responsibilities: Adesto, BridgeLux, Cambrios, Crystal IS, Innovalight and Nanomix.

	DANIEL B. WOLFE, PH.D. Chief Financial Officer and Managing Director since 2008 Mr. Wolfe joined Harris & Harris Group in 2004. Prior to joining the Company, Mr. Wolfe was a consultant to Nanosys, Inc., CW Group, and Bioscale, Inc., and was the Co-founder and President of Scientific Venture Assessments, Inc., a provider of scientific analysis of prospective investments for private equity placements and of scientific expertise to high-technology companies. He was graduated from Harvard University with a Ph.D. and A.M. in Chemistry. He was a NSF Predoctoral Fellow at Harvard, and his thesis advisor was Professor George Whitesides. He was also graduated from Rice University with a B.A. in Chemistry, where he worked with Professor Naomi Halas, and his honors included the Zevi and Bertha Salsburg Memorial Award in Chemistry and the Presidential Honor Role. He has published over 15 articles in scientific peer-reviewed journals. Portfolio responsibilities: Ensemble Discovery, Kereos, Nanosys, Nextreme Thermal Solutions, SiOnyx and Zia Laser.

	SANDRA MATRICK FORMAN, ESQ. General Counsel, Chief Compliance Officer and Director of Human Resources since 2004 Prior to joining Harris & Harris Group, Ms. Forman was an Associate at Skadden, Arps, Slate, Meagher & Flom LLP, in the Investment Management Group. She served as an intern from August to December 2000 in the office of the General Counsel, United States Department of Defense, Office of the Secretary of Defense. From June to August 1999, she served as an intern for the Honorable Ronald S. Lew, United States Federal District Court, Central District of California. She was graduated from New York University (B.A.), where her honors included National Journalism Honor Society, and from the University of California Los Angeles (J.D.), where her honors included Order of the Coif and membership on the Law Review. She is currently a member of the working group for the National Venture Capital Association model documents.

	MISTI USHIO, PH.D. Vice President and Associate since 2007 Prior to joining Harris & Harris Group, Ms. Ushio was a Technology Licensing Officer at Columbia University, where she managed the nanotechnology and materials science invention and patent portfolios. From May 1996 to May 2006, she was employed by Merck & Co., Inc., most recently as a Senior Biochemical Engineer with the Bioprocess R&D group. She is a graduate of University College London (Ph.D., Biochemical Engineering), Lehigh University (M.S., Chemical Engineering) and Johns Hopkins University (B.S., Chemical Engineering). Portfolio responsibilities: Ancora Pharmaceuticals, Biovex and Mersana Therapeutics.